Clinical Trial Update: A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Ulcerative Colitis [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating the efficacy and safety of Upadacitinib (ABT-494) in moderately to severely active ulcerative colitis completed with results pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• Upadacitinib (upadacitinib)

Snippet

Sponsor: AbbVie | Conditions: Ulcerative Colitis (UC) | Phase 3 | Status: COMPLETED | Results posted: 2021-11-26